f COVID-19―Where Are We Now

References

1. LooiM.K. Will we ever know where COVID-19 came from?BMJ2024386q157810.1136/bmj.q157839251233
   [Google Scholar]
2. ChenJ. Does COVID-19 decrease price dispersion? Recent evidence from the airline industry.Res. Econ.202478210095510.1016/j.rie.2024.100955
   [Google Scholar]
3. Cano-GuervosR. Chica-OlmoJ. Chica-GarciaJ. The effect of disruptive change on the spatial variation of commercial rental prices: The case of the COVID-19 pandemic.J. Retailing Consum. Serv.20258210411110.1016/j.jretconser.2024.104111
   [Google Scholar]
4. PalandriL. RizziC. VandelliV. FilippiniT. GhinoiA. CarrozziG. GirolamoG.D. MorliniI. CoratzaP. GiovannettiE. RussoM. SoldatiM. RighiE. AzzaliniD. BarbieriR. BechtoldP. BorsariL. CreolaG. FerrariA. FerrariD. FerrariE. FiorettiE. GattiM.G. IacuzioL. IseppiR. LugliC. MontiM. MorcianoM. Environmental, climatic, socio-economic factors and non-pharmacological interventions: A comprehensive four-domain risk assessment of COVID-19 hospitalization and death in Northern Italy.Int. J. Hyg. Environ. Health202526311447110.1016/j.ijheh.2024.11447139366078
   [Google Scholar]
5. ConteC. CipponeriE. RodenM. Diabetes mellitus, energy metabolism, and COVID-19.Endocr. Rev.202445228130810.1210/endrev/bnad03237934800
   [Google Scholar]
6. IacopettaD. CatalanoA. CeramellaJ. PellegrinoM. MarraM. ScaliE. SinicropiM. AquaroS. The ongoing impact of COVID-19 on pediatric obesity.Pediatr. Rep.202416113515010.3390/pediatric1601001338391001
   [Google Scholar]
7. LyzwinskiL. ZwickerJ.D. McdonaldS. ToughS. Psychological interventions and those with elements of positive psychology for child and youth mental health during the COVID-19 pandemic: Literature review, lessons learned, and areas for future knowledge dissemination.JMIR Pediatr. Parent.20247e5917110.2196/5917139269752
   [Google Scholar]
8. FedeliU. Barbiellini AmideiC. HanX. JemalA. Changes in cancer-related mortality during the COVID-19 pandemic in the United States.J. Natl. Cancer Inst.2024116116716910.1093/jnci/djad19137688577
   [Google Scholar]
9. CatalanoA. IacopettaD. CeramellaJ. PellegrinoM. GiuzioF. MarraM. RosanoC. SaturninoC. SinicropiM.S. AquaroS. Antibiotic-resistant ESKAPE pathogens and COVID-19: The pandemic beyond the pandemic.Viruses2023159184310.3390/v1509184337766250
   [Google Scholar]
10. KrishnaB.A. MetaxakiM. SitholeN. LandínP. MartínP. Salinas-BotránA. Cardiovascular disease and COVID-19: A systematic review.Int. J. Cardiol. Heart Vasc.20245410148210.1016/j.ijcha.2024.10148239189008
    [Google Scholar]
11. Rico-MesaJ.S. HalootJ. AnupamaB.K. AtluriS. LiuJ. KhalidU. The role and implications of COVID-19 in incident and prevalent heart failure.Curr. Heart Fail. Rep.202421548549710.1007/s11897‑024‑00677‑739042238
    [Google Scholar]
12. CeramellaJ. IacopettaD. SinicropiM.S. AndreuI. MaricondaA. SaturninoC. GiuzioF. LongoP. AquaroS. CatalanoA. Drugs for COVID-19: An update.Molecules20222723856210.3390/molecules2723856236500655
    [Google Scholar]
13. IacopettaD. CeramellaJ. CatalanoA. SaturninoC. PellegrinoM. MaricondaA. LongoP. SinicropiM.S. AquaroS. COVID-19 at a glance: An up-to-date overview on variants, drug design and therapies.Viruses202214357310.3390/v1403057335336980
    [Google Scholar]
14. KabiA.K. PalM. GujjarappaR. MalakarC.C. RoyM. Overview of hydroxychloroquine and remdesivir on severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2).J. Heterocycl. Chem.202360216518210.1002/jhet.454135942205
    [Google Scholar]
15. CatalanoA. IacopettaD. CeramellaJ. MaioA.C.D. BasileG. GiuzioF. BonomoM.G. AquaroS. WalshT.J. SinicropiM.S. SaturninoC. GeronikakiA. SalzanoG. Are nutraceuticals effective in COVID-19 and post-COVID prevention and treatment?Foods20221118288410.3390/foods1118288436141012
    [Google Scholar]
16. GasmiA. NoorS. MenzelA. KhanykN. SemenovaY. LysiukR. BeleyN. BolibrukhL. Gasmi BenahmedA. StorchyloO. BjørklundG. Potential drugs in COVID-19 management.Curr. Med. Chem.202431223245326410.2174/092986733166623071715410137461346
    [Google Scholar]
17. MitevV. Colchicine—the divine medicine against COVID-19.J. Pers. Med.202414775610.3390/jpm1407075639064010
    [Google Scholar]
18. ShafieeA. JafarabadyK. MoltazemiH. AminiM.J. RafieiM.A. AkhondiA. MozhganiS.H. Alkalinization using sodium bicarbonate for COVID-19 treatment: A systematic review and meta-analysis.J. Evid. Based Integr. Med.2024292515690X24125840310.1177/2515690X24125840338826036
    [Google Scholar]
19. MitevV. MondeshkiT. MitevaA. TashkovK. DimitrovaV. COVID-19 prophylactic effect of bromhexine hydrochloride.Preprints2024202410199810.20944/preprints202410.1998.v1
    [Google Scholar]
20. WoodsJ.A. HutchinsonN.T. PowersS.K. RobertsW.O. Gomez-CabreraM.C. RadakZ. BerkesI. BorosA. BoldoghI. LeeuwenburghC. Coelho-JúniorH.J. MarzettiE. ChengY. LiuJ. DurstineJ.L. SunJ. JiL.L. The COVID-19 pandemic and physical activity.Sports Med. Health Sci.202022556410.1016/j.smhs.2020.05.00634189484
    [Google Scholar]
21. CatalanoA. COVID-19: Could Irisin become the handyman myokine of the 21st century?Coronaviruses202011324110.2174/2666796701999200617154655
    [Google Scholar]
22. WHO coronavirus (COVID-19) dashboard. Available from: https://covid19.who.int/ (Accessed on January 24, 2025).
23. HofmeyerK.A. VenturaC.L. ArmstrongK.L. HouchensC.R. PatelS. DisbrowG.L. JohnsonR.A. BandremerA.C. BeigelJ.H. BelskiT.T. DonisR.O. JayashankarL. KoupR.A. KovacsG.R. LinkM.A. MartinsK.A. MasonR.M. StronskyS.M. WolfeD.N. Project nextgen: Developing the next generation of COVID-19 vaccines and therapeutics to respond to the present and prepare for the future.Clin. Infect. Dis.202479111512110.1093/cid/ciae07338356144
    [Google Scholar]
24. HernandezA.V. LiuA. RomanY.M. BurelaP.A. PasupuletiV. ThotaP. Carranza-TamayoC.O. Retamozo-PalaciosM. Benites-ZapataV.A. PiscoyaA. VidalJ.E. Efficacy and safety of ivermectin for treatment of non-hospitalized COVID-19 patients: A systematic review and meta-analysis of 12 randomized controlled trials with 7,035 participants.Int. J. Antimicrob. Agents202464210724810.1016/j.ijantimicag.2024.10724838908535
    [Google Scholar]
25. ZhouQ. ZhaoG. PanY. ZhangY. NiY. The efficacy and safety of fluvoxamine in patients with COVID-19: A systematic review and meta-analysis from randomized controlled trials.PLoS One2024195e030051210.1371/journal.pone.030051238753761
    [Google Scholar]
26. SilD. GautamS. SaxenaS. JoshiS. KumarD. MehtaA. JindalP. SharmaS. PandeyP. Diksha; Singh, A. Comprehensive analysis of omicron subvariants: EG.5 rise, vaccination strategies, and global impact.Curr. Drug Targets202425851752510.2174/011389450129658624043006191538726782
    [Google Scholar]
27. ParumsD.V. Editorial: A rapid global increase in COVID-19 is due to the emergence of the EG.5 (Eris) subvariant of omicron SARS-CoV-2.Med. Sci. Monit.202329e94224410.12659/MSM.94224437654205
    [Google Scholar]
28. PopovićM.E. ŠekularacG. PopovićM. The wind of change: Gibbs energy of binding and infectivity evolution of Omicron BA.2.86 Pirola, EG.5.1, XBB.1.16 Arcturus, CH.1.1 and BN.1 variants of SARS-CoV-2.Microb. Risk Anal.20242610029010.1016/j.mran.2024.100290
    [Google Scholar]
29. SARS-CoV-2 variants of concern as of 06 October 2023. 2023. Available from: https://www.ecdc.europa.eu/en/covid-19/variants-concern (Accessed on January 24, 2025).
30. Tracking SARS-CoV-2 variants. Available from: https://www.who.int/activities/tracking-SARS-CoV-2-variants (Accessed on January 24, 2025)
31. ShresthaN.K. BurkeP.C. NowackiA.S. GordonS.M. Effectiveness of the 2023-2024 Formulation of the Coronavirus Disease 2019 mRNA Vaccine against the JN. 1 Variant.medRxiv20243846590110.1101/2024.04.27.24306378
    [Google Scholar]
32. HappleC. HoffmannM. KempfA. NehlmeierI. StankovM.V. Calderon HampelN. WitteT. PöhlmannS. BehrensG.M.N. Dopfer-JablonkaA. Humoral immunity after mRNA SARS-CoV-2 omicron JN.1 vaccination.Lancet Infect. Dis.20242411e674e67610.1016/S1473‑3099(24)00603‑039341219
    [Google Scholar]
33. EMA confirms its recommendation to update the antigenic composition of authorised COVID-19 vaccines for 2024-2025. Available from: https://www.google.com/search?client=firefox-b-d&q=EMA+confirms+its+recommendation+to+update+the+antigenic+composition+of+authorised+COVID-19+vaccines+for+2024-2025 (Accessed on November 5, 2024).
34. Statement on the antigen composition of COVID-19 vaccines. Available from: https://www.who.int/news/item/26-04-2024-statement-on-the-antigen-composition-of-covid-19-vaccines (Accessed on November 5, 2024).
35. COVID-19 vaccines with WHO emergency use listing. Available from: https://extranet.who.int/prequal/vaccines/covid-19-vaccines-who-emergency-use-listing (Accessed on November 5, 2024).
36. COVID-19 Medicines. Authorized COVID-19 Vaccines. Available from: https://www.ema.europa.eu/en/human-regulatory-overview/public-health-threats/coronavirus-disease-covid-19/covid-19-medicines (Accessed on November 5, 2024).
37. COVID-19 vaccines for 2024–2025. Available from: https://www.fda.gov/emergency-preparedness-and-response/coronavirus-disease-2019-covid-19/covid-19-vaccines-2024-2025 (Accessed on November 5, 2024).
38. Plans-RubióP. What COVID-19 vaccination strategy should be implemented and which vaccines should be used in the post-pandemic era?Vaccines20241210118010.3390/vaccines1210118039460346
    [Google Scholar]